Pareto analyst Filip Wiberg downgraded Xvivo Perfusion (XVIPF) to Hold from Buy with a price target of SEK 500, down from SEK 560. The firm says it is time for the shares to “take a breather.”
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.